Two adults over 60 developed Guillain-Barre syndrome after receiving Pfizer’s respiratory syncytial virus vaccine candidate in a phase 3 trial. Now the FDA is asking the pharmaceutical giant to conduct a safety study.
Read the full post on Becker's Hospital Review - Healthcare News
